Current treatment options for meningioma

References

• Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5:1045–1054.
   PubMed Web of Science ®Google Scholar
• Zouaoui S, Darlix A, Rigau V, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2015 Jun 11.  [Epub ahead of print].
   Google Scholar
• Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821–1828.
   PubMed Web of Science ®Google Scholar
• Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. Oncologist. 2011;16:1604–1613.
   PubMed Web of Science ®Google Scholar
• Ron E, Modan B, Boice JDJ, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–1039.
   PubMed Web of Science ®Google Scholar
• Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and mortality associated with meningioma after cranial radiotherapy: a report from the childhood cancer survivor study. JCO. 2017;35:1570–1576.
   PubMed Web of Science ®Google Scholar
• Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med. 2007;357:2411–2412.
   PubMed Web of Science ®Google Scholar
• Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007;110:471–476.
   PubMed Web of Science ®Google Scholar
• Gil M, Oliva B, Timoner J, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol. 2011;72:965–968.
   PubMed Web of Science ®Google Scholar
• Carlberg M, Hardell L. Pooled analysis of Swedish case-control studies during 1997–2003 and 2007–2009 on meningioma risk associated with the use of mobile and cordless phones. Oncol Rep. 2015;33:3093–3098.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Perry A, Brat DJ. Practical surgical neuropathology: a diagnostic approach. Amsterdam, The Netherlands: Elsevier Health Sciences; 2010.
   Google Scholar
• Kshettry VR, Ostrom QT, Kruchko C, et al. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015;17:1166–1173.
   PubMed Web of Science ®Google Scholar
• Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the rare cancer network. Int J Radiat Oncol Biol Phys. 2008;71:1388–1393.
   PubMed Web of Science ®Google Scholar
• Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009;95:367–375.
   PubMed Web of Science ®Google Scholar
• Moliterno J, Cope WP, Vartanian ED, et al. Survival in patients treated for anaplastic meningioma. J Neurosurg. 2015;123:23–30.
   PubMed Web of Science ®Google Scholar
• Vaubel RA, Chen SG, Raleigh DR, et al. Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature. J Neuropathol Exp Neurol. 2016;75:44–52.
   PubMed Web of Science ®Google Scholar
• Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–e391.
   PubMed Web of Science ®Google Scholar
• Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122:4–23.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18:682–694.
   PubMed Web of Science ®Google Scholar
• Rogers CL, Perry A, Pugh S, et al. Pathology concordance levels for meningioma classification and grading in NRG oncology RTOG trial 0539. Neuro Oncol. 2016;18:565.
   PubMed Web of Science ®Google Scholar
• Combs SE, Schulz-Ertner D, Debus J, et al. Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys. 2011;81:1415–1421.
   PubMed Web of Science ®Google Scholar
• Pearson BE, Markert JM, Fisher WS, et al. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008;24:E3.
   PubMed Web of Science ®Google Scholar
• Hwang KL, Hwang WL, Bussière MR, et al. The role of radiotherapy in the management of high-grade meningiomas. Chin Clin Oncol [Internet]. 2017;6. [cited 2017 Oct 2]. Available from: http://cco.amegroups.com/article/view/15550
   Google Scholar
• Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain Tumor Pathol. 2016;33:237–247.
   PubMed Web of Science ®Google Scholar
• Boetto J, Bielle F, Sanson M, et al. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol. 2017;19:345–351.
   PubMed Web of Science ®Google Scholar
• Galani V, Lampri E, Varouktsi A, et al. Genetic and epigenetic alterations in meningiomas. Clin Neurol Neurosurg. 2017;158:119–125.
   PubMed Web of Science ®Google Scholar
• McCarthy BJ, Davis FG, Freels S, et al. Factors associated with survival in patients with meningioma. J Neurosurg. 1998;88:831–839.
   PubMed Web of Science ®Google Scholar
• Sankila R, Kallio M, Jääskeläinen J, et al. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland. Comparison of the observed and expected survival rates in a population-based series. Cancer. 1992;70:1568–1576.
   PubMed Web of Science ®Google Scholar
• Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014;16:628–636.
   PubMed Web of Science ®Google Scholar
• Kim D, Niemierko A, Hwang WL, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2017 Jun 16:1–10. [Epub ahead of print].
   Google Scholar
• Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936–942.
   PubMed Web of Science ®Google Scholar
• Kessler RA, Garzon-Muvdi T, Yang W, et al. Metastatic atypical and anaplastic meningioma: a case series and review of the literature. World Neurosurg. 2017;101:47–56.
   PubMed Web of Science ®Google Scholar
• Paix A, Waissi W, Antoni D, et al. Visceral and bone metastases of a WHO grade 2 meningioma: a case report and review of the literature. Cancer Radiother. 2017;21:55–59.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Park JH, Park ES, et al. “Wait-and-see” strategies for newly diagnosed intracranial meningiomas based on the risk of future observation failure. World Neurosurg. 2017;107:604–611.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Kim JH, Park ES, et al. A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg. 2017;127:971–980.
   PubMed Web of Science ®Google Scholar
• Cebula H, Pham TQ, Boyer P, et al. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochir (Wien). 2010;152:1955–1956.
   PubMed Web of Science ®Google Scholar
• Botella C, Coll G, Lemaire J-J, et al. [Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal]. Neurochirurgie. 2015;61:339–342.
   PubMed Web of Science ®Google Scholar
• Bernat AL, Oyama K, Hamdi S, et al. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015;157:1741–1746.
   PubMed Web of Science ®Google Scholar
• Kalamarides M, Peyre M. Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment. World Neurosurg. 2017;101:814.e7–814.e10.
   PubMed Web of Science ®Google Scholar
• Kerschbaumer J, Freyschlag CF, Stockhammer G, et al. Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg. 2016;124:137–140.
   PubMed Web of Science ®Google Scholar
• Englot DJ, Magill ST, Han SJ, et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg. 2016;124:1552.
   PubMed Web of Science ®Google Scholar
• Zada G, Başkaya MK, Shah MV. Introduction: surgical management of skull base meningiomas. Neurosurg Focus. 2017;43:Intro.
   PubMedGoogle Scholar
• Muskens IS, Briceno V, Ouwehand TL, et al. The endoscopic endonasal approach is not superior to the microscopic transcranial approach for anterior skull base meningiomas-a meta-analysis. Acta Neurochir (Wien). 2018;160(1):59–75.
   PubMed Web of Science ®Google Scholar
• Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatr. 1957;20:22–39.
   PubMed Web of Science ®Google Scholar
• Dziuk TW, Woo S, Butler EB, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol. 1998;37:177–188.
   PubMed Web of Science ®Google Scholar
• Sughrue ME, Kane AJ, Shangari G, et al. The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization grade I meningiomas. J Neurosurg. 2010;113:1029–1035.
   PubMed Web of Science ®Google Scholar
• Prabhu VC, Melian E, Germanwala AV, et al. Cranial base meningiomas. World Neurosurg [Internet]. 2017. cited 2017 Oct 16. Available from http://www.sciencedirect.com/science/article/pii/S1878875017317254
   Google Scholar
• Starke RM, Przybylowski CJ, Sugoto M, et al. Gamma Knife radiosurgery of large skull base meningiomas. J Neurosurg. 2015;122:363–372.
   PubMed Web of Science ®Google Scholar
• Patibandla MR, Lee -C-C, Sheehan J. Stereotactic radiosurgery of central skull base meningioma’s – volumetric evaluation and long-term outcomes. World Neurosurg. 2017;108:176–184.
   PubMed Web of Science ®Google Scholar
• Cho M, Joo J-D, Kim IA, et al. The role of adjuvant treatment in patients with high-grade meningioma. J Korean Neurosurg Soc. 2017;60:527–533.
   PubMed Web of Science ®Google Scholar
• Valery CA, Faillot M, Lamproglou I, et al. Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm. J Neurosurg. 2016;125:89–96.
   PubMed Web of Science ®Google Scholar
• Minniti G, Clarke E, Cavallo L, et al. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat Oncol. 2011;6:36.
   PubMed Web of Science ®Google Scholar
• Noël G, Renard A, Valéry C, et al. [Role of radiotherapy in the treatment of cerebral meningiomas]. Cancer Radiother. 2001;5:217–236.
   PubMedGoogle Scholar
• Palma L, Celli P, Franco C, et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg. 1997;86:793–800.
   PubMed Web of Science ®Google Scholar
• Walcott BP, Nahed BV, Brastianos PK, et al. Radiation treatment for WHO grade II and III meningiomas. Front Oncol [Internet]. 2013;3. cited 2017 Oct 2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759290/
   PubMedGoogle Scholar
• Peyre M, Zanello M, Mokhtari K, et al. Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. J Neurooncol. 2015;123:151–160.
   PubMed Web of Science ®Google Scholar
• Boskos C, Feuvret L, Noel G, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys. 2009;75:399–406.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kang H-C, Kim IH, et al. The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol. 2013;115:241–247.
   PubMed Web of Science ®Google Scholar
• Graffeo CS, Leeper HE, Perry A, et al. Revisiting adjuvant radiotherapy after gross total resection of World Health Organization grade II meningioma. World Neurosurg. 2017;103:655–663.
   PubMed Web of Science ®Google Scholar
• Stessin AM, Schwartz A, Judanin G, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg. 2012;117:669–675.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Hayano A, Kanayama T. Radiation-induced meningiomas: an exhaustive review of the literature. World Neurosurg. 2017;97:635.e8–644.e8.
   PubMed Web of Science ®Google Scholar
• Coskun M, Straube W, Hurkmans CW, et al. Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case reviews. Radiat Oncol. 2013;8:23.
   PubMed Web of Science ®Google Scholar
• ASTRO 2015: patients with intermediate-risk meningiomas who receive postoperative radiotherapy have a 96% 3-year progression-free survival – the ASCO post [Internet]. [ cited 2017 Oct 12]. Available from: http://www.ascopost.com/News/33973
   Google Scholar
• Jenkinson MD, Javadpour M, Haylock BJ, et al. The ROAM/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial. Trials. 2015;16:519.
   PubMed Web of Science ®Google Scholar
• Marcus HJ, Price SJ, Wilby M, et al. Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008;22:520–528.
   PubMed Web of Science ®Google Scholar
• Simon M, Boström J, Koch P, et al. Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification. J Neurol Neurosurg Psychiatr. 2006;77:767–773.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev Neurother. 2011;11:1425–1432.
   PubMed Web of Science ®Google Scholar
• Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol. 2009;92:1–6.
   PubMed Web of Science ®Google Scholar
• Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus. 2007;23:E11.
   PubMedGoogle Scholar
• Fuentes S, Chinot O, Dufour H, et al. [Hydroxyurea treatment for unresectable meningioma]. Neurochirurgie. 2004;50:461–467.
   PubMed Web of Science ®Google Scholar
• Hahn BM, Schrell UMH, Sauer R, et al. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005;74:157–165.
   PubMed Web of Science ®Google Scholar
• Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341–346.
   PubMed Web of Science ®Google Scholar
• Loven D, Hardoff R, Sever ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67:221–226.
   PubMed Web of Science ®Google Scholar
• Weston GJ, Martin AJ, Mufti GJ, et al. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16:157–160.
   PubMedGoogle Scholar
• Andersson U, Malmer B, Bergenheim AT, et al. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol. 2004;23:21–27.
   PubMed Web of Science ®Google Scholar
• Kunishio K, Kobayashi K, Kagawa M, et al. [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. Gan To Kagaku Ryoho. 2007;34:265–268.
   PubMedGoogle Scholar
• Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33:4093–4098.
   PubMed Web of Science ®Google Scholar
• Wöber-Bingöl C, Wöber C, Marosi C, et al. Interferon-alfa-2b for meningioma. Lancet. 1995;345:331.
   PubMed Web of Science ®Google Scholar
• Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271–275.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113:2146–2151.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol. 2013;2:227–235.
   PubMedGoogle Scholar
• Graillon T, Defilles C, Mohamed A, et al. Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol. 2015;124:33–43.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117:93–101.
   PubMed Web of Science ®Google Scholar
• Vranic A, Peyre M, Kalamarides M. New insights into meningioma: from genetics to trials. Curr Opin Oncol. 2012;24:660–665.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17:116–121.
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63–70.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187–193.
   PubMed Web of Science ®Google Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013;8:e59941.
   PubMed Web of Science ®Google Scholar
• Han SJ, Reis G, Kohanbash G, et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016;130:543–552.
   PubMed Web of Science ®Google Scholar
• Peyre M, Kalamarides M. Molecular genetics of meningiomas: building the roadmap towards personalized therapy. Neurochirurgie. 2014 Sep 19.  [Epub ahead of print].
   Google Scholar
• Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 2010;99:341–347.
   PubMed Web of Science ®Google Scholar
• Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077–1080.
   PubMed Web of Science ®Google Scholar
• Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016;18:649–655.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45:285.
   PubMed Web of Science ®Google Scholar
• Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002;16:1060–1065.
   PubMed Web of Science ®Google Scholar
• Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, et al. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol. 2008;18:62–70.
   PubMed Web of Science ®Google Scholar
• Peyre M, Salaud C, Clermont-Taranchon E, et al. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget. 2015;6:32713–32722.
   PubMedGoogle Scholar
• Kalamarides M, Peyre M, Giovannini M. Meningioma mouse models. J Neurooncol. 2010;99:325–331.
   PubMed Web of Science ®Google Scholar
• Peyre M, Feuvret L, Sanson M, et al. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. J Neurooncol. 2017;133:633–639.
   PubMed Web of Science ®Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598–610.
   PubMed Web of Science ®Google Scholar
• Samkari A, White J, Packer R. SHH inhibitors for the treatment of medulloblastoma. Expert Rev Neurother. 2015;15:763–770.
   PubMed Web of Science ®Google Scholar